Literature DB >> 10023009

Treatment of nasopharyngeal carcinoma: state of the art and new perspectives (review).

G Sanguineti1, R Corvo.   

Abstract

The role of radiotherapy and the current strategies to improve outcome in nasopharyngeal carcinoma are reviewed. Emphasis is on the factors, which may provide a more accurate selection of patients for more aggressive treatments. Clinical data suggest that local failure and distant metastases are separate events. Thus, strategies to optimize one of them are not expected to impact significantly on the other. Patients with advanced T stage disease, cranial nerve palsy, bulky primary lesions and well differentiated tumors may benefit from more local aggressive treatment. These include higher dose radiotherapy throughout conformal 3D radiotherapy and brachytherapy. Altered fractionation schedules and concomitant chemotherapy may also enhance the results obtained by conventional external beam radiotherapy. Patients with advanced neck disease and/or low neck nodes are candidates for additional systemic treatments as well. The role of technical innovations in radiotherapy delivery and that of altered fractionation schedules are unknown, even if results from phase II studies are promising. Regarding chemotherapy, <first generation trials> have shown some impact of chemotherapy on outcome. However, additional testing is needed in order to improve the therapeutic index and validate its rationale.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10023009

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Salivary gland function and xerostomia in southern Chinese following radiotherapy for nasopharyngeal carcinoma.

Authors:  Edmond H N Pow; Anne S McMillan; W Keung Leung; May C M Wong; Dora L W Kwong
Journal:  Clin Oral Investig       Date:  2003-08-29       Impact factor: 3.573

2.  Impact of diabetes mellitus on the risk and survival of nasopharyngeal carcinoma: a meta-analysis.

Authors:  Gang Guo; Moushun Fu; Shuxiang Wei; Ruiwan Chen
Journal:  Onco Targets Ther       Date:  2018-03-02       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.